FPI-2068

N/A

Report date: 2025/09/19 17:44:50

Base Information

Drug NameFPI-2068
Drug Alias NameFPI-2068[225Ac]-FPI-2068AZD-2068
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody diagnosticsBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) +[6] 
Mechanisms of ActionEpidermal growth factor receptor erbB1 antagonistsHepatocyte growth factor receptor inhibitors
TargetsEpidermal growth factor receptor erbB1Hepatocyte growth factor receptor
Therapy Area/IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungStomach Neoplasms +[8] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesFusion Pharmaceuticals IncAstrazeneca Plc
China Registration ClassN/A

Develop Information

Active CompaniesAstrazeneca Plc
Inactive CompaniesFusion Pharmaceuticals Inc
Active IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungStomach Neoplasms +[7] 
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A